Výsledky vyhledávání

P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease

Autor: E Sharma, J Kotecha, A Akintimehin, S Ray, S H Anderson, J Mawdsley, P M Irving, M A Samaan

Publikováno v: Journal of Crohn's and Colitis. 16:i431-i433

Background Iron deficiency anaemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD). Ferric salts are the cheapest preparations at approximately £2 per treatment course compared to more costly alternative oral prep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6463254b0fb67b9dca9437a355c13b15
https://doi.org/10.1093/ecco-jcc/jjab232.580

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lower gastrointestinal bleeding in pregnancy: Differential diagnosis, assessment and management

Autor: Lisa Story, Anita Banerjee, J Mawdsley, S Rafique, B Singh, N Samadi

Publikováno v: Obstetric Medicine

Rectal bleeding is a common symptom experienced by pregnant women. Although the majority of cases are attributable to benign conditions such as haemorrhoids and anal fissures, other more serious diagnoses such as inflammatory bowel disease and malign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da29394644c6d9955132fc1ef7ece3a4
https://doi.org/10.1177/1753495x20948300

Zobrazit plný text záznamu

P618 Pre-operative oral enteral nutritional optimisation for Crohn’s disease: A retrospective UK tertiary IBD centre cohort study

Publikováno v: Journal of Crohn's and Colitis. 16:i545-i546

Background Low quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve post-operative outcomes in patients with small bowel Crohn’s disease (CD). It is not standard practice in most centres. We aimed to test the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ab438165635562f97246c498e767376
https://doi.org/10.1093/ecco-jcc/jjab232.744

Zobrazit plný text záznamu

P567 Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort study

Autor: S Honap, E Sharma, S Ray, J Mawdsley, S Anderson, M Samaan, P Pavlidis, P Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i510-i511

Background Serious adverse events (SAE), including venous thromboembolism (VTE) and major adverse cardiovascular events (MACE), have been reported in tofacitinib post-marketing trials. However, safety data extending beyond six months in the real worl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20706a6414f5f795762d124e775f6fe6
https://doi.org/10.1093/ecco-jcc/jjab232.693

Zobrazit plný text záznamu

P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program

Autor: A C Moore, D Russell, R Dart, S Dias, S Ghuman, B Petri, E Sharma, S Ray, S Anderson, J Mawdsley, P M Irving, M A Samaan

Publikováno v: Journal of Crohn's and Colitis. 16:i401-i402

Background Biosimilars have delivered significant cost savings, increasing access to biologics for many patients. While numerous studies have demonstrated no difference in efficacy between originators and biosimilars, the impact of switching between

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::747815233de0eb0079466a8f8221e879
https://doi.org/10.1093/ecco-jcc/jjab232.538

Zobrazit plný text záznamu

P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?

Autor: E Routledge, S Meade, E Sharma, S Zeki, S Ray, S Anderson, J Sanderson, J Mawdsley, M Samaan

Publikováno v: Journal of Crohn's and Colitis. 16:i408-i409

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative provides recommendations on treatment targets for patients with Crohn’s disease (CD). The Simple Endoscopic Score for CD (SES-CD) is a validated endoscop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e8429ed4eae2d0d3f9505f32ae0e90
https://doi.org/10.1093/ecco-jcc/jjab232.549

Zobrazit plný text záznamu

P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study

Autor: S Honap, E Sharma, S Ray, J Mawdsley, S Anderson, M Samaan, P Pavlidis, P Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i414-i415

Background Tofacitinib is an oral small molecule inhibitor licensed for the treatment of ulcerative colitis (UC). Whilst real world data has been presented, outcomes beyond, 26 weeks are limited. The objective of this study was to assess the persiste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c24ece19c59755a69c66a0747c6a02b
https://doi.org/10.1093/ecco-jcc/jjab232.557

Zobrazit plný text záznamu

P332 Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD)

Autor: A Duff, A De Petrillo, D Reynolds, E Bangura, P Pavilidis, J Mawdsley

Publikováno v: Journal of Crohn's and Colitis. 16:i350-i350

Background ACT is a psychological therapy designed to increase psychological flexibility and improve how people relate to difficulties. It has been found to be efficacious with a range of difficulties (Gloster et al, 2020) but is increasingly used to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9059347eaf75e6cf9b80c00cf57a9c1
https://doi.org/10.1093/ecco-jcc/jjab232.459

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání